$ORIB
Orion Bliss Corp.

2024 Q3 Form 10-Q Financial Statement

#000168316824006089 Filed on August 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit -$13.51K -$33.62K
YoY Change -59.83%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.51K -$33.62K
YoY Change -59.83% 289.34%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.038M shares 3.038M shares 3.038M shares
Diluted Shares Outstanding 3.038M shares 3.038M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $740.00 $0.00 $331.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $740.00 $1.324K $465.00
YoY Change 59.14% -83.27% 247.01%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $134.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $740.00 $1.324K $465.00
Total Long-Term Assets $134.00 $0.00
Total Assets $874.00 $1.324K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $103.6K $90.52K $70.93K
YoY Change 46.03% 102.26% 97.7%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $103.6K $90.52K $70.93K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$123.7K -$110.2K -$91.42K
YoY Change 35.26% 90.59% 145.42%
Common Stock $304.00 $304.00 $304.00
YoY Change 0.0% 0.0% 46.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$102.7K -$89.19K -$70.46K
YoY Change
Total Liabilities & Shareholders Equity $874.00 $1.324K $465.00
YoY Change 87.96% -83.27% 247.01%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q3
OPERATING ACTIVITIES
Net Income -$13.51K -$33.62K
YoY Change -59.83% 289.34%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$13.51K -$33.62K
YoY Change -59.83% 289.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $13.06K $26.17K
YoY Change -50.12% 203.07%
NET CHANGE
Cash From Operating Activities -$13.51K -$33.62K
Cash From Investing Activities
Cash From Financing Activities $13.06K $26.17K
Net Change In Cash -$450.00 -$7.450K
YoY Change -93.96%
FREE CASH FLOW
Cash From Operating Activities -$13.51K -$33.62K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123658 usd
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2024Q3 dei Entity Shell Company
EntityShellCompany
true
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3038000 shares
CY2024Q3 us-gaap Escrow Deposit
EscrowDeposit
740 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
740 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1190 usd
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
134 usd
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
134 usd
CY2024Q3 us-gaap Assets
Assets
874 usd
CY2024Q2 us-gaap Assets
Assets
1324 usd
CY2024Q3 ORIB Accounts Payable Related Party
AccountsPayableRelatedParty
40000 usd
CY2024Q2 ORIB Accounts Payable Related Party
AccountsPayableRelatedParty
37000 usd
CY2024Q3 ORIB Director Loan
DirectorLoan
63572 usd
CY2024Q2 ORIB Director Loan
DirectorLoan
53517 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
103572 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
90517 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
304 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
304 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20656 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20656 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123658 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110153 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-102698 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89193 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
874 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1324 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13505 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33623 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13505 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33623 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13505 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33623 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1925 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1725 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26690 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-28415 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20760 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29182 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-36837 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-52356 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89193 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13505 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-102698 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13505 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33623 usd
CY2024Q3 us-gaap Increase Decrease In Intangible Assets Current
IncreaseDecreaseInIntangibleAssetsCurrent
-0 usd
CY2023Q3 us-gaap Increase Decrease In Intangible Assets Current
IncreaseDecreaseInIntangibleAssetsCurrent
-0 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13505 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33623 usd
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2024Q3 ORIB Proceeds From Accounts Payable Related Party Debt
ProceedsFromAccountsPayableRelatedPartyDebt
3000 usd
CY2023Q3 ORIB Proceeds From Accounts Payable Related Party Debt
ProceedsFromAccountsPayableRelatedPartyDebt
3000 usd
CY2024Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
10055 usd
CY2023Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
23173 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13055 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26173 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-450 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7450 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1190 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7781 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
740 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
331 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110153 usd
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zWJpj4tj9PB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zOwgVfzhKNfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zg794hpKsvok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial Statement Reclassification</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2836 usd
CY2024Q3 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2836 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25968 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25968 usd
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
123658 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-006089-index-headers.html Edgar Link pending
0001683168-24-006089-index.html Edgar Link pending
0001683168-24-006089.txt Edgar Link pending
0001683168-24-006089-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
orib-20240731.xsd Edgar Link pending
orionbliss_i10q-073124.htm Edgar Link pending
orion_ex3101.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
orib-20240731_def.xml Edgar Link unprocessable
orib-20240731_cal.xml Edgar Link unprocessable
orib-20240731_lab.xml Edgar Link unprocessable
orib-20240731_pre.xml Edgar Link unprocessable
orionbliss_i10q-073124_htm.xml Edgar Link completed
orion_ex3201.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending